Canada Approves Second Generic Version of Ozempic
Canada has approved a second generic version of Novo Nordisk's diabetes drug Ozempic, produced by Apotex. This approval increases competition in the market for semaglutide, a drug used to treat type 2 diabetes. The move is expected to impact pricing and availability of the medication in Canada.
Tickers: $NVO
Topics: Apotex generic drugs Novo Nordisk pharmaceuticals regulatory approval